Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
1900 participants
OBSERVATIONAL
2019-02-04
2024-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
HCCBloodTest for Detection of Hepatocellular Carcinoma (HCC)
NCT03804593
Risk Factors and Molecular Genomics of U.S. Patients With Chronic Liver Disease and Hepatocellular Cancer
NCT01034865
ALTUS: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased Risk
NCT05064553
Development and Validation of a Multi-target, Blood-based NAFLD Diagnosis Test
NCT05108415
National Liver Cancer Screening Trial
NCT06084234
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Subjects at high risk for developing HCC due to liver cirrhosis and who are eligible for liver cancer surveillance as determined by the patient's physician and who meet all inclusion and exclusion eligibility criteria as described in this protocol, will be invited to participate in this study. Subjects will then read, understand and sign the Informed Consent Form and the HIPAA Authorization Agreement for Medical Records Form.
For each subject upon enrollment, the following blood analytes will also be determined: creatinine, prothrombin time, bilirubin, blood platelet count, ALT, AST and ALP. The results of all clinical laboratory tests will be recorded by use of the subject's Case Report Form. Whole blood samples drawn for the multi-analyte blood test will be collected (according to the instructions provided with each sample collection kit) by using the multi-analyte Sample Collection, Stabilization and Shipping Kit, and shipped to a central LAM laboratory for testing. Samples will be assayed by laboratory technicians blinded to the results of any other testing. Within the same clinical visit as the blood draws (when possible), subjects will undergo conventional ultrasound to examine the liver. Every subject will then go on to diagnostic imaging by multiphasic MRI. The results of diagnostic imaging will primarily be scored by LI-RADS score and the number and size of any malignant lesions identified will be recorded. The images of all MRI, CT, or ultrasound will be saved and uploaded for evaluation by a blinded, centralized team of radiologists to confirm diagnosis. Any biopsy results or surgical pathology results that are generated for study subjects as part of current clinical practice will also be recorded.
Study procedures will consist of conventional ultrasound to examine the liver, providing blood samples for testing with the multi-analyte blood test and other conventional blood analytes, and diagnostic imaging by multiphasic MRI.
Upon enrolling in the study, subjects will commence the Initial Surveillance Visit (t=0 months). During the Initial Surveillance Visit, all enrolled subjects will undergo ultrasound to examine the liver and provide blood samples for the multi-analyte blood test and for determining conventional blood analytes. Every subject will then go on to diagnostic imaging by multiphasic MRI. The results of diagnostic imaging will primarily be scored by a Liver Reporting and Data System (LI-RADS) score. The data of all diagnostic imaging by MRI will be saved and uploaded for evaluation by a blinded, centralized team of radiologists, which will be used as the basis of the clinical truth for all subjects.
After the Initial Surveillance Visit (t=0 months), subjects with an indeterminant HCC finding by MRI (LI-RADS 3) will be recommended to up to three Follow-Up Visits (t=6 months, t=12 months, and t=18 months) to attempt to resolve the clinical truth for these subjects. Each Follow-Up Visit will consist of an ultrasound to examine the liver, providing blood samples for the multi-analyte blood test , as well as diagnostic imaging by multiphasic MRI.
Although not required by this clinical protocol, any biopsy or surgical pathology results, or any additional imaging (such as multiphasic CT) that are generated for study subjects as part of current clinical practice will also be recorded for each subject and the results shall be made available to the Sponsor if performed within 6 months of a scheduled Visit. Biopsy and surgical pathology results that indicate a malignancy will be used in place of diagnostic imaging as the clinical truth for each subject if performed within 6 months of a scheduled visit and prior to database lock.
All study-related procedures will occur during the Study Duration Period, which consists of the Initial Surveillance Visit for all subjects and up to three Follow-Up Visits for subjects with an initial indeterminant HCC finding (LI-RADS 3) by diagnostic imaging. After this Study Duration Period, no study related blood draws, imaging or procedures will occur for these subjects.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
men or women between 21-84
Multi-analyte blood test alone versus ultrasound in subjects diagnosed with liver cirrhosis
Multi-analyte blood Test
intended for the qualitative detection of DNA methylation profiles associated with hepatocellular carcinoma in cell-free DNA derived from patient whole blood specimens.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Multi-analyte blood Test
intended for the qualitative detection of DNA methylation profiles associated with hepatocellular carcinoma in cell-free DNA derived from patient whole blood specimens.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subject is able to read, comprehend and sign the Informed Consent Document
* Subject is willing and able to undergo liver cancer surveillance by ultrasound and the multi-analyte blood Test
* Subject is able and willing to undergo diagnostic imaging by multiphasic MRI with contrast according to the Study Protocol
* Subject has been diagnosed with liver cirrhosis by one or more of the following methods:
1. Clinical diagnosis by blood analytes (APRI ≥ 1.5 or Bonacini cirrhosis discriminant score ≥ 8 or Lok index \> 0.5)
2. Ultrasound and Elastography \> 12.5 kPa (Vibration-controlled transient elastography, Point shear wave elastography, Two-dimensional shear wave ultrasound and transient elastography or Magnetic Resonance Elastography)
3. Diagnostic imaging by CT or MRI (liver cirrhosis indicated on radiology report)
4. Liver biopsy (liver cirrhosis indicated on pathology report)
Exclusion Criteria
* Subject has previously been diagnosed with a primary liver cancer or a non-liver cancer that has metastasized
* Subject has previously submitted a blood sample to Helio Health (HELIO) through a separate clinical protocol
* Subject is unable or unwilling to submit blood samples for testing, undergo ultrasound or undergo diagnostic imaging by multiphasic MRI with contrast as required for the Study Protocol
* Subject has any internal metallic device or fragment, including but not limited to: A pacemaker, artificial joint or valve, surgical clips, pins, plates, screws, wire mesh or shrapnel
* It is unsafe for the subject to receive an MRI contrast dye due to pregnancy or severe kidney disease
* Subject would not routinely be recommended for HCC surveillance
* Subject received an abdominal ultrasound or diagnostic imaging by MRI or CT to image the liver within the past 5 months
21 Years
84 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Helio Genomics
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Taggart, PhD
Role: STUDY_DIRECTOR
Helio Genomics
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
AZ Liver Health (Chandler)
Chandler, Arizona, United States
AZ Liver Health (Glendale, Peoria)
Peoria, Arizona, United States
AZ Liver Health (Tucson)
Tucson, Arizona, United States
Banner University Hospital (University of Arizona Tucson)
Tucson, Arizona, United States
Alliance Research Centers
Irvine, California, United States
University of South California
Los Angeles, California, United States
Cedars-Sinai Medical Center
Los Angeles, California, United States
Stanford University
Palo Alto, California, United States
University of Colorado Hospital - Anschutz Cancer Pavilion
Aurora, Colorado, United States
Covenant Metabolic LLC
Fort Myers, Florida, United States
University of Florida Clinical and Translational Science Institute
Gainesville, Florida, United States
University of Miami - Schiff Center for Liver Diseases
Miami, Florida, United States
Gastroenterology Group of Naples
Naples, Florida, United States
Covenant Metabolics LLC
Sarasota, Florida, United States
Atlanta Gastroenterology
Atlanta, Georgia, United States
Piedmont Research Institute
Atlanta, Georgia, United States
Loyola University Medical Center
Maywood, Illinois, United States
St Luke's Hospital of Kansas City
Kansas City, Kansas, United States
University of Louisville
Louisville, Kentucky, United States
Tulane University Health Sciences Center
New Orleans, Louisiana, United States
Ochsner Clinic Foundation
New Orleans, Louisiana, United States
Louisiana Research Center, LLC
Shreveport, Louisiana, United States
Kansas City Research Institute (KCRI)
Kansas City, Missouri, United States
PMG Research of Winston-Salem
Winston-Salem, North Carolina, United States
University of Cincinnati College of Medicine
Cincinnati, Ohio, United States
Gastro One in Memphis
Memphis, Tennessee, United States
Quality Medical
Nashville, Tennessee, United States
Liver Center of Texas
Dallas, Texas, United States
Methodist Dallas Medical Center
Dallas, Texas, United States
SouthTexas Research Institute
Edinburg, Texas, United States
Texas Gastro Clinic
El Paso, Texas, United States
Konkord Research
Houston, Texas, United States
Texas Liver Institute - American Research Corp.
San Antonio, Texas, United States
Impact Research Institute
Waco, Texas, United States
Digestive & Liver Disease Specialists (DLDS) - Norfolk
Norfolk, Virginia, United States
VA Richmond
Richmond, Virginia, United States
Harborview Medical Center (University of Washington)
Seattle, Washington, United States
Liver Institute Northwest
Seattle, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
LAM-2018-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.